Veracyte, Inc. Acquires Convergent Genomics for $150M

What Happened

• Veracyte, Inc. announced that it entered into an Agreement and Plan of Merger on September 10, 2026, and completed the merger on September 14, 2026. Compass Merger Sub, Inc. merged with and into Convergent Genomics, with Convergent continuing as a wholly owned subsidiary of Veracyte.
• Veracyte paid aggregate cash consideration of $150 million at closing (subject to customary purchase-price adjustments for cash, indebtedness, transaction expenses and net working capital) and may pay up to an additional $30 million tied to specified milestones related to Convergent’s UroAmp publications and reimbursement efforts. Convergent is a genomic diagnostics company focused on bladder cancer and its UroAmp urine tumor DNA technology.

Key Details

• Agreement signed: September 10, 2026; Merger closed: September 14, 2026.
• Cash consideration at closing: $150 million (subject to customary adjustments).
• Potential additional earnout: up to $30 million based on UroAmp publication and reimbursement milestones.
• Transaction adds Convergent’s UroAmp and proprietary urine tumor DNA technology to Veracyte’s roadmap; Merger Agreement includes customary representations, warranties, covenants and post‑closing indemnities.
• Veracyte furnished a press release announcing the closing (Exhibit 99.1); the Merger Agreement is filed as Exhibit 2.1 to the 8‑K.

Why It Matters

• The acquisition brings a bladder‑cancer urine‑based genomic test (UroAmp) and related technology into Veracyte’s product pipeline, potentially expanding its diagnostic offerings and commercial opportunities.
• The deal is primarily cash‑funded ($150M now, up to $30M contingent), which is material to Veracyte’s capital allocation and may affect near‑term cash resources; the final purchase price is subject to standard post‑closing adjustments.
• Investors should note the filing of the Merger Agreement and press release for additional contract terms and disclosures; the agreement contains customary indemnities and certain confidential portions were redacted in the exhibit filing.